What causes the death of dopaminergic neurons in Parkinson's disease?
暂无分享,去创建一个
D James Surmeier | Joshua A Goldberg | D. Surmeier | J. Goldberg | Jaime N Guzman | Javier Sanchez-Padilla | J. Sánchez-Padilla | J. N. Guzmán | J. Sánchez-Padilla | Jaime N. Guzmán | Javier Sánchez-Padilla
[1] J. Olsen,et al. L‐type calcium channel blockers and Parkinson disease in Denmark , 2009, Annals of neurology.
[2] Robert E Burke,et al. A critical evaluation of the Braak staging scheme for Parkinson's disease , 2008, Annals of neurology.
[3] Alessandro Stefani,et al. Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones , 1994, British journal of pharmacology.
[4] G. Obermair,et al. Expression and 1,4-Dihydropyridine-Binding Properties of Brain L-Type Calcium Channel Isoforms , 2009, Molecular Pharmacology.
[5] B. Bean. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[6] M. Madesh,et al. Calcium signaling and apoptosis. , 2003, Biochemical and biophysical research communications.
[7] T. Ishikawa,et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] C. O’Brien,et al. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. , 1991, Archives of neurology.
[9] Aj Lees,et al. Parkinson's disease (vol 373, pg 2055, 2009) , 2009 .
[10] Robert W. Taylor,et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.
[11] D. James Surmeier,et al. ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease , 2007, Nature.
[12] M. Mattson,et al. Superoxide Flashes in Single Mitochondria , 2008, Cell.
[13] B. Bean,et al. Subthreshold Sodium Current from Rapidly Inactivating Sodium Channels Drives Spontaneous Firing of Tuberomammillary Neurons , 2002, Neuron.
[14] Hansjürgen Bratzke,et al. Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.
[15] J. C. Greene,et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[16] Tamas L. Horvath,et al. Uncoupling Protein-2 Is Critical for Nigral Dopamine Cell Survival in a Mouse Model of Parkinson's Disease , 2005, The Journal of Neuroscience.
[17] S. Hunot,et al. Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.
[18] H. Braak,et al. Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.
[19] R. Palmiter,et al. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior , 2009, Proceedings of the National Academy of Sciences.
[20] C. Tanner,et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.
[21] A. Koschak,et al. α1D (Cav1.3) Subunits Can Form L-type Ca2+ Channels Activating at Negative Voltages* , 2001, The Journal of Biological Chemistry.
[22] P. Shepard,et al. Apamin‐sensitive Ca2+-activated K+ channels regulate pacemaker activity in nigral dopamine neurons , 1996, Neuroreport.
[23] P. Riederer,et al. Time course of nigrostriatal degeneration in parkinson's disease , 1976, Journal of Neural Transmission.
[24] M. Beal,et al. Excitotoxicity and nitric oxide in parkinson's disease pathogenesis , 1998, Annals of neurology.
[25] O. Hornykiewicz. Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.
[26] Changan Jiang,et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.
[27] S. Jick,et al. Use of antihypertensives and the risk of Parkinson disease , 2008, Neurology.
[28] Alain Dagher,et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years , 2008, Nature Medicine.
[29] Pasko Rakic,et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. T. Williams,et al. Membrane properties of rat locus coeruleus neurones , 1984, Neuroscience.
[31] B. Amini,et al. Calcium dynamics underlying pacemaker-like and burst firing oscillations in midbrain dopaminergic neurons: a computational study. , 1999, Journal of neurophysiology.
[32] K. Petersen,et al. Altered Brain Mitochondrial Metabolism in Healthy Aging as Assessed by in vivo Magnetic Resonance Spectroscopy , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[33] Kamran Khodakhah,et al. Two Intracellular Pathways Mediate Metabotropic Glutamate Receptor-Induced Ca2+ Mobilization in Dopamine Neurons , 2003, The Journal of Neuroscience.
[34] Ole A. Andreassen,et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.
[35] H. Uylings,et al. Gender‐related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients , 2008, Movement disorders : official journal of the Movement Disorder Society.
[36] D. S. Albers,et al. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism , 2005, Amino Acids.
[37] K. Jellinger. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. , 2009, Biochimica et biophysica acta.
[38] D. Sulzer,et al. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease , 2007, Trends in Neurosciences.
[39] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[40] A. Grace,et al. The control of firing pattern in nigral dopamine neurons: single spike firing , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[41] W. Schultz,et al. Dopamine neurons of the monkey midbrain: contingencies of responses to active touch during self-initiated arm movements. , 1990, Journal of neurophysiology.
[42] D. Murchison,et al. Calcium buffering systems and calcium signaling in aged rat basal forebrain neurons , 2007, Aging cell.
[43] A. Kupsch,et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level , 1996, Brain Research.
[44] K. Takakusaki,et al. Ionic mechanisms involved in the spontaneous firing of tegmental pedunculopontine nucleus neurons of the rat , 1997, Neuroscience.
[45] D. Sulzer,et al. Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.
[46] M. Goldberg,et al. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention , 2010, Neurobiology of Disease.
[47] A. Blair,et al. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. , 2006, American journal of epidemiology.
[48] Wade K. Smith,et al. Disease‐specific patterns of locus coeruleus cell loss , 1992, Annals of neurology.
[49] D. German,et al. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease , 1991, Annals of neurology.
[50] R. Bakay,et al. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to parkinsonism , 2007, Neurobiology of Disease.
[51] J. Wickens,et al. Space, time and dopamine , 2007, Trends in Neurosciences.
[52] M. Elstner,et al. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions , 2008, Journal of Neurology.
[53] Kim J. Krishnan,et al. Age related mitochondrial degenerative disorders in humans , 2008, Biotechnology journal.
[54] D. Nicholls. Oxidative Stress and Energy Crises in Neuronal Dysfunction , 2008, Annals of the New York Academy of Sciences.
[55] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[56] S. Overeem,et al. Hypocretin (orexin) loss in Parkinson's disease. , 2007, Brain : a journal of neurology.
[57] Ping Hx,et al. Apamin-sensitive Ca2+-activated K+ channels regulate pacemaker activity in nigral dopamine neurons , 1996 .
[58] M. Beal,et al. Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.
[59] T. Gasser. Mendelian forms of Parkinson's disease. , 2009, Biochimica et biophysica acta.
[60] R. Dixon,et al. Age-related cognitive deficits mediated by changes in the striatal dopamine system. , 2000, The American journal of psychiatry.
[61] I. Bezprozvanny. Calcium signaling and neurodegenerative diseases. , 2009, Trends in molecular medicine.
[62] S. Minucci,et al. Protein Kinase C ß and Prolyl Isomerase 1 Regulate Mitochondrial Effects of the Life-Span Determinant p66Shc , 2007, Science.
[63] S. Goto,et al. Calbindin‐D28K in the basal ganglia of patients with parkinsonism , 1992, Annals of neurology.
[64] John Hardy,et al. Parkinson's disease , 2009, The Lancet.
[65] H. Okano,et al. Functional properties of dopaminergic neurones in the mouse olfactory bulb , 2005, The Journal of physiology.
[66] D. Harman,et al. Free‐Radical Theory of Aging , 1994, Antioxidants & redox signaling.
[67] M. Eisenberg,et al. Calcium channel blockers: an update. , 2004, The American journal of medicine.
[68] D. James Surmeier,et al. Robust Pacemaking in Substantia Nigra Dopaminergic Neurons , 2009, The Journal of Neuroscience.
[69] I. Engberg,et al. Nifedipine‐ and omega‐conotoxin‐sensitive Ca2+ conductances in guinea‐pig substantia nigra pars compacta neurones. , 1993, The Journal of physiology.
[70] C. Shults. Therapeutic role of coenzyme Q(10) in Parkinson's disease. , 2005, Pharmacology & therapeutics.
[71] C. Wilson,et al. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. , 2000, Journal of neurophysiology.
[72] P. Benfield,et al. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. , 1990, Drugs.
[73] H. Haas,et al. Calcium‐dependent prepotentials contribute to spontaneous activity in rat tuberomammillary neurons. , 1996, The Journal of physiology.
[74] M. Breteler,et al. Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.
[75] H. Chapel,et al. CLINICAL RELEVANCE OF SPECIFIC IgG ANTIBODIES TO CARDIOLIPIN , 1989, The Lancet.
[76] Hypoxia increases ROS signaling and cytosolic Ca(2+) in pulmonary artery smooth muscle cells of mouse lungs slices. , 2010, Antioxidants & redox signaling.
[77] Tullio Pozzan,et al. Microdomains of intracellular Ca2+: molecular determinants and functional consequences. , 2006, Physiological reviews.
[78] B. Szende,et al. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. , 2004, Neurotoxicology.
[79] Wade K. Smith,et al. Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization , 1989, Annals of neurology.
[80] R. Rizzuto. Intracellular Ca2+ pools in neuronal signalling , 2001, Current Opinion in Neurobiology.
[81] D. D. Di Monte,et al. Aging of the nigrostriatal system in the squirrel monkey , 2004, The Journal of comparative neurology.
[82] J. Langston,et al. Aetiology of Parkinsońs disease , 1983 .
[83] Joachim Klose,et al. Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.
[84] Dong-Kug Choi,et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[85] A. Koschak,et al. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. , 2006, Biochemical Society transactions.
[86] G. Bernardi,et al. L-Type Calcium Channels Mediate a Slow Excitatory Synaptic Transmission in Rat Midbrain Dopaminergic Neurons , 1998, The Journal of Neuroscience.
[87] M. Vila,et al. MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease , 2004, Journal of bioenergetics and biomembranes.
[88] Greenamyre Jt,et al. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. , 1991 .
[89] B. Bean,et al. Roles of Subthreshold Calcium Current and Sodium Current in Spontaneous Firing of Mouse Midbrain Dopamine Neurons , 2007, The Journal of Neuroscience.
[90] Sten Orrenius,et al. Calcium: Regulation of cell death: the calcium–apoptosis link , 2003, Nature Reviews Molecular Cell Biology.
[91] R. Gillis,et al. Hyperpolarization-activated currents, IH and IKIR, in rat dorsal motor nucleus of the vagus neurons in vitro. , 1994, Journal of neurophysiology.
[92] D. Calne,et al. AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.
[93] D. Vigetti,et al. A potential reservoir of immature dopaminergic replacement neurons in the adult mammalian olfactory bulb , 2009, Pflügers Archiv - European Journal of Physiology.
[94] J Q Trojanowski,et al. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[95] E. Hirsch,et al. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter , 2003, Experimental Neurology.
[96] T. Dawson,et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase , 2007, Proceedings of the National Academy of Sciences.
[97] Devin Oglesbee,et al. Investigating Mitochondrial Redox Potential with Redox-sensitive Green Fluorescent Protein Indicators* , 2004, Journal of Biological Chemistry.
[98] C. Saper,et al. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease , 1985, Annals of neurology.
[99] C. Mannella,et al. Structural and functional features and significance of the physical linkage between ER and mitochondria , 2006, The Journal of cell biology.
[100] S. Prusiner,et al. Is Parkinson's disease a prion disorder? , 2009, Proceedings of the National Academy of Sciences.
[101] Connie Marras,et al. Occupation and risk of parkinsonism: a multicenter case-control study. , 2009, Archives of neurology.
[102] W. Schultz. Multiple dopamine functions at different time courses. , 2007, Annual review of neuroscience.
[103] B. Pakkenberg,et al. Histological changes of the dopaminergic nigrostriatal system in aging , 2004, Cell and Tissue Research.
[104] Dwight C. German,et al. Mitochondria mass is low in mouse substantia nigra dopamine neurons: Implications for Parkinson's disease , 2007, Experimental Neurology.
[105] A. Hung,et al. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? , 2007, Current opinion in neurology.
[106] Raimund Mannhold. Calciumantagonisten vom Dihydropyridintyp: Medizinisch‐chemische und molekularpharmakologische Eigenschaften , 1995 .
[107] Takeshi Sakurai,et al. Hypocretin/Orexin Excites Hypocretin Neurons via a Local Glutamate Neuron—A Potential Mechanism for Orchestrating the Hypothalamic Arousal System , 2002, Neuron.
[108] G. Aghajanian,et al. Pacemaker potentials of serotonergic dorsal raphe neurons: Contribution of a low‐threshold Ca2+ conductance , 1987, Synapse.
[109] Stanley Fahn,et al. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? , 2005, Journal of Neurology.
[110] J. Tepper,et al. Electrophysiologically identified nigral dopaminergic neurons intracellularly labeled with HRP: light-microscopic analysis , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[111] A. Lang,et al. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder , 2006, Neurology.
[112] K. Jellinger. A critical reappraisal of current staging of Lewy-related pathology in human brain , 2008, Acta Neuropathologica.
[113] R. Hauser,et al. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.
[114] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[115] Jerome M. Siegel,et al. Hypocretin (orexin) cell loss in Parkinson’s disease , 2007, Brain : a journal of neurology.
[116] John P. Horn,et al. Cav1.3 Channel Voltage Dependence, Not Ca2+ Selectivity, Drives Pacemaker Activity and Amplifies Bursts in Nigral Dopamine Neurons , 2009, The Journal of Neuroscience.
[117] Sunhong Kim,et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.
[118] Belen Gago,et al. Uncoupling protein‐2 promotes nigrostriatal dopamine neuronal function , 2006, The European journal of neuroscience.
[119] B. A. Brooks,et al. Midbrain Dopaminergic Cell Loss in Parkinson's Disease and MPTP‐Induced Parkinsonism: Sparing of Calbindin‐D25k—Containing Cells a , 1992, Annals of the New York Academy of Sciences.
[120] Takeshi Sakurai,et al. Hypothalamic Orexin Neurons Regulate Arousal According to Energy Balance in Mice , 2003, Neuron.
[121] A. Reichert,et al. Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin , 2007, The Journal of Neuroscience.
[122] A. Graybiel,et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.
[123] Charles J. Wilson,et al. An Intrinsic Neuronal Oscillator Underlies Dopaminergic Neuron Bursting , 2009, The Journal of Neuroscience.
[124] A. Schapira. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. , 1999, The Lancet. Neurology.
[125] M. Berridge,et al. The versatility and universality of calcium signalling , 2000, Nature Reviews Molecular Cell Biology.
[126] D. Murchison,et al. Low-voltage activated calcium currents increase in basal forebrain neurons from aged rats. , 1995, Journal of neurophysiology.
[127] M. Bevan,et al. Cellular Mechanisms Underlying Burst Firing in Substantia Nigra Dopamine Neurons , 2009, The Journal of Neuroscience.
[128] F. Fujiyama,et al. Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum , 2009, The Journal of Neuroscience.
[129] D. Wallace. A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine , 2005, Annual review of genetics.
[130] Elisabet Englund,et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.
[131] T. Gasser,et al. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. , 2009, Free radical biology & medicine.
[132] T. Hastings,et al. Biomedicine. Parkinson's--divergent causes, convergent mechanisms. , 2004, Science.
[133] J. Kordower,et al. Age‐related changes in dopamine transporters and accumulation of 3‐nitrotyrosine in rhesus monkey midbrain dopamine neurons: Relevance in selective neuronal vulnerability to degeneration , 2008, The European journal of neuroscience.
[134] A. J. Lambert,et al. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. , 2004, Free radical biology & medicine.